The promise of an exciting new drug that inhibits the mutant B-RAF protein in skin cancer is marred by the fact that most patients relapse within a year. Fresh data hint at how such resistance emerges. See Letters p.968 & p.973
This is a preview of subscription content, log in via an institution to check access.
References
Davies, H. et al. Nature 417, 949–954 (2002).
Bollag, G. et al. Nature 467, 596–599 (2010).
Flaherty, K. T. et al. N. Engl. J. Med. 363, 809–819 (2010).
Johannessen, C. M. et al. Nature 468, 968–972 (2010).
Nazarian, R. et al. Nature 468, 973–977 (2010).
Kantarjian, H. et al. N. Engl. J. Med. 362, 2260–2270 (2010).
Saglio, G. et al. N. Engl. J. Med. 362, 2251–2259 (2010).
Whittaker, S. et al. Sci. Transl. Med. 2, 35ra41 (2010).
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. Nature 464, 427–430 (2010).
Hatzivassiliou, G. et al. Nature 464, 431–435 (2010).
Heidorn, S. J. et al. Cell 140, 209–221 (2010).
Engelman, J. A. et al. Science 316, 1039–1043 (2007).
Montagut, C. et al. Cancer Res. 68, 4853–4861 (2008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Solit, D., Sawyers, C. How melanomas bypass new therapy. Nature 468, 902–903 (2010). https://doi.org/10.1038/468902a
Published:
Issue Date:
DOI: https://doi.org/10.1038/468902a
- Springer Nature Limited
This article is cited by
-
Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling
Oncogene (2016)
-
Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?
BMC Medicine (2014)
-
Drug repositioning for personalized medicine
Genome Medicine (2012)
-
Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling
The EMBO Journal (2012)
-
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
Nature Genetics (2012)